Bioventix Plc · LSE:BVXP
Bioventix — Investor Presentation (March 2024)
15 slides from Bioventix's investor presentation, Mar 25, 2024
Slide 1: Bioventix plc
Bioventix plc 25 March 2024 04 Bioventix
Slide 2: Antibodies and Blood Testing
2 Antibodies and Blood Testing ▪Bioventix creates and manufactures sheep monoclonal antibodies (SMAs). Customers incorporate these antibodies in reagent packs for use on automated blood-testing machines antigen antibody ▪Superior antibodies can facilitate improved tests ▪Bioventix sells liquid “phys
Slide 3: Diagnostic Applications for SMAs
3 Diagnostic Applications for SMAs Vitamin D Thyroid function Fertility heart attack & heart Drug testing (25-OH vitamin D) (thyroxine, T3, failure (testosterone, estradiol, (THC) TSH) progesterone, cortisol) (troponin, BNPs) ▪Bioventix has a portfolio of ~20 antibodies that are sold globally to in
Slide 4: Antibodies and Business Dynamics
4 Antibodies and Business Dynamics ▪Projects can be internally driven or sponsored by customers +1 year ▪Bioventix takes about 1 year to create new antibodies Prototype test Old test 2-4 years ▪Even for established diagnostics, customers take 2-4 years to prototype tests, = 3-5 years total conduct f
Slide 5: Key Interim Financials
5 Key Interim Financials £ (‘000) year to ½ year to ½ year to Cavendish 30.6.23 30.12.22 30.12.23 forecast 2023/24 Sales 12,820 5,900 6,680 14,000 (+13%) P/(L) before tax 10,130 4,520 5,240 11,400 (+16%) (adjusted) Corporation tax 1,760 790 1,220 (+54%) P/(L) after tax 8,370 3,730 4,020 8,900 (+8%)
Slide 6: ▪This data relates to the last complete financial year 2022/23 ▪Siemens troponin revenues will
6 ▪This data relates to the last complete financial year 2022/23 ▪Siemens troponin revenues will terminate in June 2032
Slide 7: Sales Commentary for the Period
7 Sales Commentary for the Period ▪ Vitamin D and core antibody sales were in line with expectations ▪ Chinese physical product sales and associated royalties increased significantly over the period ▪ Troponin sales were a little below expectation but we believe that this reflects temporary operatio
Slide 8: Research: Alzheimer's Disease
8 (A) Tau PET (T) (T) (N) ▪Alzheimer’s is complex and is ▪The disease progresses many different amongst individuals years before symptoms appear ▪Changes at a cell level include ▪Neurodegeneration in the Amyloid PET (A) amyloid plaques outside neurons brain is clear in later disease and tau tangles
Slide 9: Tau Update
9 Tau PET (T) Tau Update ▪Research – Early detection of AD & pTau217: confusingly, pTau217 is currently the preferred blood biomarker for the early phase of amyloid build-up (A) – First generation SMAs have facilitated the University of Gothenburg “UGOT” pTau217 assay. More cohort groups are Amyloid
Slide 10: Other Pipeline Developments
10 Other Pipeline Developments high Amyloid (Pre-Diagnostics) Tau (Alzheimer’s, own-risk) ← Increasing potential value Secretoneurin (CardiNor) medium Low Industrial biomonitoring Pyrene biomonitoring (benzene, isocyanates) Low Medium high Increasing probability of success → ▪Amyloid (Pre-Diagnostic
Slide 11: Bioventix Strategy
11 Bioventix Strategy ▪ Seek novel clinical diagnostic biomarkers that suit our antibody technology and identify partner collaborator labs (eg Tau & University of Gothenburg) ▪ Continue to focus on antibody technology development • Identify antibody technologies that are compatible with existing cor
Slide 12: Bioventix Lab, Farnham
12 Bioventix Lab, Farnham ▪ Technology development ▪ Purification and assay ▪ Cell culture ▪ Bioreactor production ▪Staff continuity has remained high with no recent departures or retirements
Slide 13: Bioventix Directors
13 Bioventix Directors ▪Peter Harrison, CEO ▪Ian Nicholson, Chairman ▪>30 years experience of ▪>30 years experience of antibody technology at commercial development within Celltech, KS Biomedix & biotechnology including Bioventix Amersham, Celltech, Chroma, Clinigen, Consort Medical & F2G ▪Peter rem
Slide 14: Significant Shareholders
14 Significant Shareholders Institution Shares % (1000s) Sanford DeLand 668 12.8 Gresham House 578 11.1 Total shares = 5,219,656 (Mar 2024) Liontrust 571 11.0 Hargreaves Lansdown Stockbrokers 343 6.6 Rathbones Investment Mgmt (inc Investec) 324 6.2 Peter Harrison 297 5.7 ▪From permissions, other Dan
Slide 15: Conclusions and Outlook
15 Conclusions and Outlook ▪ Sales of our vitamin D antibody and other core SMAs have been in line with expectation ▪ Sales to customers in China increased significantly ▪ Troponin revenues were a little below expectation but confidence in analysts’ forecasts is maintained ▪ Research work on Tau for